Timothy Cloughesy, MD
Professor and Director
Department of Neurology, Neuro-Oncology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California
Timothy Cloughesy, MD, has disclosed that he is cofounder, major stock holder, consultant, and board member of Katmai Pharmaceuticals; member of the board for the 501c3 Global Coalition for Adaptive Research; holds stock options in Notable Labs; holds stock in Chimerix and receives milestone payments and possible future royalties; is a member of the scientific advisory board for Cure Brain Cancer Foundation and Break Through Cancer; has provided paid consulting services to AbbVie, Agios, Amgen, Bayer, Bristol-Myers Squibb, Boehinger Ingelheim, Boston Biomedical, BrainStorm, Celgene, Cortice, Deciphera, DNATrix, Gan & Lee, GCAR, Genocea, GW Pharma, Human Longevity, Immvira, Inovio, Insys, Jubilant, Karyopharm, Katmai, Kintara, Kiyatec, Lilly, Medefield, Medqia Trizel, Medscape, Merck, Notable labs, Novartis, Novocure, Novogen, Odonate Therapeutics QED, Pascal Biosciences, Pfizer, ProNai, Puma, Roche, Sapience, SDP, Sunovion, Tocagen, Tyme, VBI, VBL, Vigeo Therapeutics, and Wellcome Trust; and has contracts with UCLA for the Brain Tumor Program with AbbVie, Agios, Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, Boston Biomedical, Deciphera, DNAtrix, Karyopharm, Kazia, Merck, Novartis, Oncoceutics, Oncovir, Orbus, and Tocagen.